Member Exclusive

Why the FDA’s CAR-T approval sends strong signal to cell therapy industry: an interview with Martin Lamb

In this interview, Martin Lamb, TrakCel, discusses the recent FDA approval of Novartis’ CAR-T cell therapy.

Go to the profile of RegMedNet
Sep 13, 2017

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.


No comments yet.